TY - JOUR
T1 - Native and bioengineered extracellular vesicles for cardiovascular therapeutics
AU - de Abreu, Ricardo Cerqueira
AU - Fernandes, Hugo
AU - Martins, Paula A. da Costa
AU - Sahoo, Susmita
AU - Emanueli, Costanza
AU - Ferreira, Lino
N1 - Funding Information:
The authors were supported by the Portuguese National Funding Agency for Science, Research and Technology (fellowship to R.C.d.A. (SFRH/SFRH/BD/129317/2017) and Project Exo-Heart (POCI-01-0145-FEDER-029919) to H.F.). P.A.d.C.M. is funded by a Dutch Heart Foundation grant (NHS2015T066). P.A.d.C.M., C.E. and L.F. are members of the EEU COST Action CardioRNA CA17129. S.S. has received grants from the NIH (HL124187, HL140469, HL148786 and NYSTEM C32562GG) and Transatlantic Foundation Leducq. C.E. has received funding via a British Heart Foundation (BHF) programme grant, personal Chair awards (RG/15/5/31446 and CH/15/1/31199) and the BHF Centre of Vascular Regeneration. L.F. is supported by Program Interreg Atlantic Space through the European Fund for Regional Development (Project NeuroAtlantic (EAPA_791/2018) and Project 2IQBIONEURO (0624_2IQBIONEURO_6_E)) and EC Project ERAatUC (669088).
Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2020/11
Y1 - 2020/11
N2 - Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant to the treatment of cardiovascular diseases. These endogenous vesicles have certain properties that allow them to survive in the extracellular space, bypass biological barriers and deliver their biologically active molecular cargo to recipient cells. Moreover, EVs can be bioengineered to increase their stability, bioactivity, presentation to acceptor cells and capacity for on-target binding at both cell-type-specific and tissue-specific levels. Bioengineering of EVs involves the modification of the donor cell before EV isolation or direct modification of the EV properties after isolation. The therapeutic potential of native EVs and bioengineered EVs has been only minimally explored in the context of cardiovascular diseases. Efforts to harness the therapeutic potential of EVs will require innovative approaches and a comprehensive integration of knowledge gathered from decades of research into molecular-compound delivery. In this Review, we outline the endogenous properties of EVs that make them natural delivery agents as well as the features that can be improved by bioengineering. We also discuss the therapeutic applications of native and bioengineered EVs to cardiovascular diseases and examine the opportunities and challenges that need to be addressed to advance this research area, with an emphasis on clinical translation.Extracellular vesicles are a heterogeneous group of natural particles that can deliver their biologically active molecular cargo to recipient cells. In this Review, the authors outline the endogenous properties of extracellular vesicles that make them natural delivery agents and the features that can be improved by bioengineering for the treatment of cardiovascular diseases.
AB - Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant to the treatment of cardiovascular diseases. These endogenous vesicles have certain properties that allow them to survive in the extracellular space, bypass biological barriers and deliver their biologically active molecular cargo to recipient cells. Moreover, EVs can be bioengineered to increase their stability, bioactivity, presentation to acceptor cells and capacity for on-target binding at both cell-type-specific and tissue-specific levels. Bioengineering of EVs involves the modification of the donor cell before EV isolation or direct modification of the EV properties after isolation. The therapeutic potential of native EVs and bioengineered EVs has been only minimally explored in the context of cardiovascular diseases. Efforts to harness the therapeutic potential of EVs will require innovative approaches and a comprehensive integration of knowledge gathered from decades of research into molecular-compound delivery. In this Review, we outline the endogenous properties of EVs that make them natural delivery agents as well as the features that can be improved by bioengineering. We also discuss the therapeutic applications of native and bioengineered EVs to cardiovascular diseases and examine the opportunities and challenges that need to be addressed to advance this research area, with an emphasis on clinical translation.Extracellular vesicles are a heterogeneous group of natural particles that can deliver their biologically active molecular cargo to recipient cells. In this Review, the authors outline the endogenous properties of extracellular vesicles that make them natural delivery agents and the features that can be improved by bioengineering for the treatment of cardiovascular diseases.
KW - CELL-DERIVED EXOSOMES
KW - IMPROVE CARDIAC-FUNCTION
KW - PROMOTE ANGIOGENESIS
KW - CARDIOMYOCYTE APOPTOSIS
KW - INDUCE ANGIOGENESIS
KW - IN-VITRO
KW - DELIVERY
KW - THERAPY
KW - BIODISTRIBUTION
KW - MICRORNAS
U2 - 10.1038/s41569-020-0389-5
DO - 10.1038/s41569-020-0389-5
M3 - (Systematic) Review article
C2 - 32483304
SN - 1759-5002
VL - 17
SP - 685
EP - 697
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 11
ER -